EP4367252A4 - PHARMACEUTICAL COMPOSITION OF NON-ENVELOPED VIRUS - Google Patents

PHARMACEUTICAL COMPOSITION OF NON-ENVELOPED VIRUS

Info

Publication number
EP4367252A4
EP4367252A4 EP22838112.5A EP22838112A EP4367252A4 EP 4367252 A4 EP4367252 A4 EP 4367252A4 EP 22838112 A EP22838112 A EP 22838112A EP 4367252 A4 EP4367252 A4 EP 4367252A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
enveloped virus
enveloped
virus
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22838112.5A
Other languages
German (de)
French (fr)
Other versions
EP4367252A2 (en
Inventor
Lina Igorevna FEDORENKO
Ekaterina Aleksandrovna LOMKOVA
Aleksandr Olegovich IAKOVLEV
Aleksandra Aleksandrovna SOZONOVA
Marina Konstantinovna DVORIANKINA
Dmitry Valentinovich MOROZOV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocad JSC
Original Assignee
Biocad JSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021120143A external-priority patent/RU2860958C2/en
Application filed by Biocad JSC filed Critical Biocad JSC
Publication of EP4367252A2 publication Critical patent/EP4367252A2/en
Publication of EP4367252A4 publication Critical patent/EP4367252A4/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EP22838112.5A 2021-07-08 2022-07-04 PHARMACEUTICAL COMPOSITION OF NON-ENVELOPED VIRUS Pending EP4367252A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021120143A RU2860958C2 (en) 2021-07-08 Pharmaceutical composition of non-enveloped virus
PCT/RU2022/050212 WO2023282796A2 (en) 2021-07-08 2022-07-04 Pharmaceutical composition of non-enveloped virus

Publications (2)

Publication Number Publication Date
EP4367252A2 EP4367252A2 (en) 2024-05-15
EP4367252A4 true EP4367252A4 (en) 2025-04-30

Family

ID=84800844

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22838112.5A Pending EP4367252A4 (en) 2021-07-08 2022-07-04 PHARMACEUTICAL COMPOSITION OF NON-ENVELOPED VIRUS

Country Status (12)

Country Link
EP (1) EP4367252A4 (en)
CN (1) CN117999353A (en)
AR (1) AR126417A1 (en)
CL (1) CL2024000062A1 (en)
CO (1) CO2024000073A2 (en)
CR (1) CR20240004A (en)
EC (1) ECSP24001599A (en)
JO (1) JOP20240003A1 (en)
MA (1) MA63861A1 (en)
MX (1) MX2024000472A (en)
WO (1) WO2023282796A2 (en)
ZA (1) ZA202400124B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4651900A1 (en) * 2023-01-19 2025-11-26 uniQure biopharma B.V. Pharmaceutical formulations of gene delivery vehicles
WO2025051970A2 (en) * 2023-09-06 2025-03-13 Dinaqor Ag Methods of treatment of hypertrophic cardiomyopathy with aav gene therapy vectors and therapeutic formulations
WO2025114524A1 (en) * 2023-11-30 2025-06-05 Uniqure Biopharma B.V. Formulations for viral drug products
WO2025263459A1 (en) * 2024-06-17 2025-12-26 学校法人神戸薬科大学 Biopharmaceutical composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130216499A1 (en) * 2012-02-17 2013-08-22 Wenlin Huang Compositions of recombinant human endostatin adenovirus injections and methods of production
WO2015040002A1 (en) * 2013-09-19 2015-03-26 Crucell Holland B.V. Improved adenovirus formulations
WO2018128689A1 (en) * 2016-11-04 2018-07-12 Baxalta Incorporated Adeno-associated virus formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116280A2 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
AU2019310459A1 (en) * 2018-07-24 2021-02-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130216499A1 (en) * 2012-02-17 2013-08-22 Wenlin Huang Compositions of recombinant human endostatin adenovirus injections and methods of production
WO2015040002A1 (en) * 2013-09-19 2015-03-26 Crucell Holland B.V. Improved adenovirus formulations
WO2018128689A1 (en) * 2016-11-04 2018-07-12 Baxalta Incorporated Adeno-associated virus formulations

Also Published As

Publication number Publication date
MA63861A1 (en) 2024-10-31
CR20240004A (en) 2024-06-11
CN117999353A (en) 2024-05-07
EP4367252A2 (en) 2024-05-15
ECSP24001599A (en) 2024-02-29
JOP20240003A1 (en) 2024-01-08
MX2024000472A (en) 2024-02-12
ZA202400124B (en) 2024-11-27
WO2023282796A2 (en) 2023-01-12
CL2024000062A1 (en) 2024-06-14
WO2023282796A3 (en) 2023-02-16
AR126417A1 (en) 2023-10-11
CO2024000073A2 (en) 2024-04-29

Similar Documents

Publication Publication Date Title
EP4367252A4 (en) PHARMACEUTICAL COMPOSITION OF NON-ENVELOPED VIRUS
EP3914252A4 (en) PHARMACEUTICAL COMPOSITION OF NILOTINIB
DK4440702T3 (en) THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION
EP3996716C0 (en) Connections for the treatment of influenza virus infections
EP3981390A4 (en) PHARMACEUTICAL COMPOSITION OF LACOSAMIDE AND ITS PHARMACEUTICAL PREPARATION
EP4028059A4 (en) STABLE MEDICINAL COMPOSITIONS OF CANNABIDIOL
EP3906019C0 (en) Pharmaceutical compositions of furosemide
EP4073071A4 (en) USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES
EP3946316A4 (en) PHARMACEUTICAL COMPOSITIONS OF CANNABIDIOL
EP4415708A4 (en) COMPOSITIONS FOR ADMINISTRATION OF CANNABINOIDS
EP4122483A4 (en) ORAL PHARMACEUTICAL COMPOSITION
EP4023227A4 (en) PHARMACEUTICAL COMPOSITION AND ITS APPLICATION
EP4508077A4 (en) Compositions for the prevention or treatment of influenza infections
EP3741845A4 (en) RECOMBINANT VACCINE VIRUS AND PHARMACEUTICAL COMPOSITION CONSISTING OF IT
EP3582759A4 (en) BIOEQUIVALENT PHARMACEUTICAL COMPOSITION OF VORTIOXETINE BROMHYDRATE
EP4456887A4 (en) PHARMACEUTICAL COMPOSITION
EP3399040A4 (en) PROCESS FOR THE PREPARATION OF A PROTEIN CAPSID PROTEIN OF TYPE 2 PORCINIC CIRCOVIRUS AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
EP3880183A4 (en) PHARMACEUTICAL PREPARATION OF FRUQUINTINIB AND ITS USE
CR20240192A (en) Pharmaceutical compositions of efruxifermin
EP4275007C0 (en) DRYING OF PHARMACEUTICAL POWS
DOP2025000121A (en) PHARMACEUTICAL COMPOSITION OF NON-ENVELOPED VIRUSES
EP4452295A4 (en) Pharmaceutical composition for the treatment of viral infections
EP4176868A4 (en) STABLE PHARMACEUTICAL COMPOSITION
BR112021002126A2 (en) Virus dispensing composition, and method for preparing a virus dispensing composition.
EP4329729A4 (en) PHARMACEUTICAL COMPOSITION OF PEMBROLIZUMAB AND ITS USE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231221

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250402

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/10 20170101ALI20250327BHEP

Ipc: A61K 9/00 20060101ALI20250327BHEP

Ipc: A61K 47/02 20060101ALI20250327BHEP

Ipc: A61K 47/40 20060101ALI20250327BHEP

Ipc: A61K 47/34 20170101ALI20250327BHEP

Ipc: A61K 47/26 20060101ALI20250327BHEP

Ipc: A61K 47/18 20170101ALI20250327BHEP

Ipc: A61K 9/19 20060101ALI20250327BHEP

Ipc: A61K 9/08 20060101ALI20250327BHEP

Ipc: A61K 35/76 20150101ALI20250327BHEP

Ipc: C12N 7/00 20060101ALI20250327BHEP

Ipc: C12N 15/86 20060101AFI20250327BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20251216